{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:32:19Z","timestamp":1779006739039,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Ustekinumab (UST) is indicated for the treatment of Crohn\u2019s disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) maintenance has been proposed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p> The primary endpoint of our study was to evaluate the efficacy and safety of maintenance IV UST treatment in Inflammatory Bowel Disease (IBD) patients who present with partial response or loss of response to subcutaneous (SC) UST. <\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p> We performed a monocentric observational retrospective study including patients with active IBD on maintenance treatment with IV UST. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> The clinical response and remission was analyzed at week 12, defined as either Harvey\u2013Bradshaw Index\u2009\u2a7d\u20094 for CD or partial Mayo Score\u2009\u2a7d\u20092 for UC. The reduction of objective markers of disease activity, fecal calprotectin, and C-reactive protein was evaluated. Moreover, UST trough levels were measured pre- and post-UST IV maintenance and any adverse events were assessed. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> We included 23 patients. Clinical remission at week 12 was achieved by 43.5% of the patients. The proportion of patients in clinical response after 12\u2009weeks on UST IV maintenance was 82.6%. After a median follow-up of 9.3\u2009months all patients remained on IV UST maintenance. No adverse events were recorded in any patient for the duration of the study. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> IV UST maintenance treatment was able to recapture response in most of the patients who had lost response to SC maintenance. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562848231191670","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T05:13:21Z","timestamp":1692940401000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing"],"prefix":"10.1177","volume":"16","author":[{"given":"Federico","family":"Arg\u00fcelles-Arias","sequence":"first","affiliation":[{"name":"Virgen Macarena University Hospital (Seville), Sevilla, Spain"},{"name":"University of Seville, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-5142","authenticated-orcid":false,"given":"Teresa","family":"Vald\u00e9s Delgado","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital (Seville), Av. Dr. Fedriani s\/n, Seville 41009, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Maldonado P\u00e9rez","sequence":"additional","affiliation":[{"name":"Virgen Macarena University Hospital (Seville), Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Gonz\u00e1lez Antu\u00f1a","sequence":"additional","affiliation":[{"name":"Virgen Macarena University Hospital (Seville), Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Castro Laria","sequence":"additional","affiliation":[{"name":"Virgen Macarena University Hospital (Seville), Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"bibr1-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001074"},{"key":"bibr2-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"bibr3-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"bibr4-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1324-3"},{"key":"bibr5-17562848231191670","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19388"},{"key":"bibr6-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.60"},{"key":"bibr7-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12940"},{"key":"bibr8-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab081"},{"key":"bibr9-17562848231191670","first-page":"272","volume":"114","author":"Lorenzo Gonz\u00e1lez L","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"bibr10-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.10.002"},{"key":"bibr11-17562848231191670","first-page":"116","volume":"28","author":"Hermida P\u00e9rez B","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"key":"bibr12-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"bibr13-17562848231191670","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002047"},{"key":"bibr14-17562848231191670","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051894"},{"key":"bibr15-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06932-4"},{"key":"bibr16-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231153560"},{"key":"bibr17-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16802"},{"key":"bibr18-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.10.002"},{"key":"bibr19-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15784"},{"key":"bibr20-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwac017"},{"key":"bibr21-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.560"},{"key":"bibr22-17562848231191670","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac067"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848231191670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848231191670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848231191670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:11:35Z","timestamp":1740759095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848231191670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"alternative-id":["10.1177\/17562848231191670"],"URL":"https:\/\/doi.org\/10.1177\/17562848231191670","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17562848231191670"}}